Medical Xpress
How a tiny circle of repeat offenders poisoned 100s of gold-standard medical trials for over a decade
A small network of repeat fraudsters fabricated data across hundreds of randomized controlled trials over more than a decade, corrupting the most trusted tier of medical evidence. Because RCTs anchor systematic reviews, meta-analyses, and clinical guidelines, the damage extends far beyond the retracted papers themselves. The scandal exposes a structural vulnerability in research integrity: when bad actors target the top of the evidence hierarchy, the rot flows silently downstream into real-world medical practice.
Read article →Medical Xpress
Study suggests some Alzheimer's symptoms may begin outside the brain
Alzheimer's disease may not be strictly a brain disorder. New research from the University of Central Florida suggests that some movement-related symptoms associated with the disease originate outside the brain entirely. The finding could prompt a fundamental rethink of how Alzheimer's is diagnosed and treated.
Read article →Medical Xpress
GLP-1 in joint fluid may let weight-loss drugs target arthritis directly
Researchers at Aarhus University have discovered GLP-1 receptors in joint fluid, opening the door to a potential new use for weight-loss drugs like semaglutide in treating arthritis. The finding suggests these medications — already celebrated for their effects on obesity and diabetes — could be redirected to target joint inflammation directly. If confirmed in further studies, this could represent a significant shift in how both inflammatory and degenerative arthritis conditions are managed.
Read article →Medical Xpress
Menstrual cycle reshapes nearly 200 blood proteins, offering a broader view of women's health
A new study from Aarhus University has found that the menstrual cycle influences nearly 200 proteins in the bloodstream, marking the first time researchers have documented its broad, systemic impact on the female body. Published in Nature Medicine, the findings reveal that hormonal fluctuations throughout the cycle reach far beyond reproductive biology. The research has significant implications for how clinical diagnostics and reference ranges are developed for women, as cycle phase may need to be factored into blood-based health assessments.
Read article →Medical Xpress
Global trial shows novel treatment for triple-negative breast cancer nearly doubles survival
A landmark phase III clinical trial has found that the antibody-drug conjugate datopotamab deruxtecan nearly doubles survival rates in patients with previously untreated advanced triple-negative breast cancer, one of the most aggressive and difficult-to-treat forms of the disease. The TROPION-Breast02 trial, led by researchers from the National Cancer Centre Singapore and published in the Annals of Oncology, marks a significant step forward in treatment options for a patient population with historically poor outcomes. The findings position Dato-DXd as a compelling new frontline therapy for advanced TNBC.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →